Supplementary Material for: Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study

Background/Aims: The aim of this study was to analyze
the short- and long-term outcomes of infliximab (IFX) treatment to cure
steroid-refractory ulcerative colitis (UC) and related prognostic
factors. Methods: Retrospective data were collected from
125 patients with steroid-refractory UC who received IFX treatment at
our center from July 2005 to November 2013. The Lichtiger clinical
activity index score was calculated at baseline, 2 weeks, 6 weeks, and 1
year, and the cumulative non-colectomy rate following IFX
administration was estimated. Remission rate prognostic factors and the
cumulative colectomy rate prognostic factors were evaluated using
multivariate logistic regression analysis and multivariate Cox
regression analysis, respectively. Results: Remission
rates at 2 weeks, 6 weeks, and 1 year were 46, 58, and 45%,
respectively. The 1-, 3-, and 5-year cumulative non-colectomy rates were
80, 78, and 75%, respectively. Previous treatment with calcineurin
inhibitors was a significant prognostic factor for lower remission and
cumulative non-colectomy rates, whereas concomitant immunomodulators was
a significant prognostic factor for the higher remission rate. Gender
(female) was a prognostic factor for higher remission rate at 1 year and
higher cumulative non-colectomy rate. Conclusions: This
study revealed good short- and long-term outcomes of IFX treatment in
patients with steroid-refractory UC. Previous treatment with calcineurin
inhibitors was a prognostic factor for poor outcomes of IFX treatment,
whereas concomitant immunomodulators and gender (female) were prognostic
factors for good outcomes.